Melanoma & Skin Cancer

Data from the RELATIVITY-047 trial, which evaluated relatlimab plus nivolumab in untreated, advanced melanoma were reviewed and clinical implications of these data were discussed.

Dr Michael Atkins and Dr Evan Lipson highlight some of the current unmet needs in the treatment of patients with metastatic melanoma.

Experts discuss the use of BRAF and MEK inhibitors as first-line treatments for patients with metastatic melanoma.

Dr Michael Atkins and Dr Evan Lipson review data from the DREAMseq trial, which evaluated nivolumab plus ipilimumab, in treatment-naïve patients with BRAFV600-mutated melanoma.

Dr Lipson discusses the significance of the regulatory decision for relatlimab and nivolumab, updated data from the RELATIVITY-047 trial, adverse effects clinicians associated with the doublet, and the potential next steps for this therapy in melanoma.

Howard D. Edington, MD, discusses the use of talimogene laherparepvec in melanoma.

John M. Kirkwood, MD, discusses the utilization of ipilimumab and nivolumab in patients with melanoma with brain metastases.

Dr Michael Atkins and Dr Evan Lipson introduce and discuss a patient with unresectable stage IV metastatic melanoma.

Dr Evan Lipson provides a brief overview of metastatic melanoma including information on incidence and prognosis. He also covers the current state of biomarker testing for patients recently diagnosed with metastatic melanoma.

Howard D. Edington, MD, discusses the utilization of tumor-infiltrating lymphocyte therapy in melanoma.

The addition of novel anti–LAG-3 antibody relatlimab-rmbw to antiPD-1 antibody nivolumab offers treatment-naïve patients with unresectable or metastatic melanoma an efficacious and tolerable immunotherapy treatment option.

Helen Heng-Shan Moon, MD, discusses the utilization of relatlimab plus nivolumab in patients with unresectable or metastatic melanoma.

Marlana M. Orloff, MD, overviews how pivotal efficacy and safety data of tebentafusp will improve the treatment paradigm for adult patients with HLA-A*02:01–positive unresectable or metastatic uveal melanoma.

Jason Luke, MD, FACP, reviews key points from each presentation from an Institutional Perspectives in Cancer webinar on melanoma and provides perspective on the practice-changing benefits of therapies moving into earlier lines of treatment.

Howard D. Edington, MD, discusses the importance of prevention strategies in melanoma.

Hussein A. Tawbi, MD, PhD, discusses the utilization of relatlimab plus nivolumab in unresectable or metastatic melanoma.

Helen Heng-Shan Moon, MD, discusses the FDA approval of relatlimab plus nivolumab in patients with unresectable or metastatic melanoma.

The combination of the CD40 agonist antibody sotigalimab and pembrolizumab demonstrated a favorable safety profile and led to immunologic changes that correlated with clinical response in patients with unresectable stage III or IV metastatic melanoma.

Howard D. Edington, MD, discusses the evolving treatment paradigm of melanoma.

The combination of nivolumab and ipilimumab demonstrated a statistically significant improvement in progression-free survival vs ipilimumab alone as second-line therapy in previously treated patients with stage III unresectable or stage IV melanoma.

The addition of BO-112 to pembrolizumab demonstrated efficacy and safety in patients with advanced melanoma who were resistant to anti–PD-1 therapies, according to final results from the phase 2 SPOTLIGHT203 trial.

Nivolumab in combination with a PD-L1/IDO peptide vaccine displayed encouraging efficacy and survival results among patients with metastatic melanoma.

The combination of the oncolytic vaccine vusolimogene oderparepvec and nivolumab continued to drive encouraging responses with acceptable tolerability in patients with melanoma and other skin cancers.

The FDA has provided positive feedback regarding Iovance Biotherapeutics, Inc.’s proposed matrix of potency assays for an upcoming biologics license application seeking the approval of lifileucel in the treatment of patients with metastatic melanoma.

Fixed-duration systemic therapies have gained some traction in hematologic malignancies, where advances in drug development and sequencing strategies have afforded investigators the opportunity to conduct trials.